首页> 美国卫生研究院文献>other >Development of Inhibitors of Receptor Protein Tyrosine Phosphatase β/ζ (PTPRZ1) as Candidates for CNS disorders
【2h】

Development of Inhibitors of Receptor Protein Tyrosine Phosphatase β/ζ (PTPRZ1) as Candidates for CNS disorders

机译:受体蛋白酪氨酸磷酸酶β/ζ(PTPRZ1)抑制剂作为中枢神经系统疾病候选物的开发

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A new series of blood-brain barrier permeable molecules designed to mimic the activity of Pleiotrophin in the CNS has been designed and synthesized. These compounds exert their action by interacting with the intracellular domain PD1 of the Protein Tyrosine-Phosphatase Receptor Z1 (PTPRZ1), and inhibiting its tyrosine phosphatase activity. The most potent compounds >10a and >12b (IC50 = 0,1 μM) significantly increase the phosphorylation of key tyrosine residues of PTPRZ1 substrates involved in neuronal survival and differentiation, and display protective effects against amphetamine-induced toxicity. Docking and molecular dynamics experiments have been used to analyze the binding mode and to explain the observed selectivity against PTP1B. An In vivo experiment has demonstrated that >10a can cross the BBB, thus promoting the possibility of moving forward these candidates for the development of drugs for the treatment of CNS disorders, such as drug addiction and neurodegenerative diseases.
机译:设计并合成了一系列新的血脑屏障渗透性分子,旨在模拟中枢神经系统中Pleiotrophin的活性。这些化合物通过与酪氨酸磷酸酶受体Z1(PTPRZ1)的胞内域PD1相互作用并抑制其酪氨酸磷酸酶活性而发挥作用。最有效的化合物> 10a 和> 12b (IC50 = 0.1μM)显着增加了参与神经元存活和分化的PTPRZ1底物的关键酪氨酸残基的磷酸化,并显示出保护性对苯丙胺引起的毒性的影响。对接和分子动力学实验已用于分析结合模式并解释观察到的对PTP1B的选择性。体内实验表明,> 10a 可以穿越血脑屏障,从而促进了发展这些候选药物来开发用于治疗中枢神经系统疾病(例如成瘾和神经退行性疾病)的药物的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号